TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03110640

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: anti-CD19 CAR-T
Description: Ex vivo-expanded autologous T cells modified to express CD19 CAR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Patients were given cyclophosphamide 500mg/m2/day on day -4 and fludarabine at 25 mg/m2/day on day -4, day -3, and day -2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Patients were given cyclophosphamide 500mg/m2/day on day -4.
Study: NCT05651035

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: oral feeding
Description: In experimental group infants: Preterms in this group will be breastfed by their own mother.~In control group infants: Preterms in this group will be fed by the researcher by putting the baby's own mother's milk in the bottle. During feeding, the preterm will be placed on the lap by the researcher in a standing position on the same mother's breast, and will be given a raised side-lying position. In this position, the preterm's head and body will be elevated 45-60 degrees with the help of a small pillow. While the researcher will support the preterm's head, neck and shoulder with one hand, he will control the bottle with the other hand. By touching the preterm's nipple to the preterm's lips, the preterm will be prepared for feeding, and the bottle will be placed in the baby's mouth with the mouth opening and the tongue lowering. During feeding, stimulating movements such as pushing the bottle back and forth in the mouth, which will lead the newborn to suck faster, will not be made.
Study: NCT03369119

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast 4 Mg Oral Granule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Study: NCT03904693

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FDC macitentan/tadalafil
Description: Film-coated tablet with 10 mg macitentan and 40 mg tadalafil, to be administered orally once daily.
Study: NCT06533891

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: DPA enriched n-3
Description: 4 g/d DPA enriched n-3 concentrate (\~980 mg DPA, 380 mg EPA, 1720 mg DHA)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: n-3 control
Description: 4 g/d n-3 control (\~980 oleic acid, 380 mg EPA, 1720 mg DHA)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 4 g/d placebo control (light olive oil)
Study: NCT03638102

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Sleep extension
Description: Sleep extension aims to increase sleep duration for at least 30 minutes using weekly coaching

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Healthy living
Description: Participants will receive weekly health education
Study: NCT02152631

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Abemaciclib
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Erlotinib
Description: Administered orally
Study: NCT04057352

Intervention type: DEVICE
Group type: OTHER
Intervention: Citadel Embolization Device
Description: The Citadel Embolization Device is intended to endovascularly obstruct or occlude blood flow in intracranial aneurysms.
Study: NCT03692078

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTDN product 1
Description: Oral tobacco-derived nicotine product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTDN product 1
Description: Oral tobacco-derived nicotine product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTDN product 2
Description: Oral tobacco-derived nicotine product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OTDN product 2
Description: Oral tobacco-derived nicotine product

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tobacco Cessation
Description: Tobacco Cessation
Study: NCT03904693

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Macitentan 10 mg
Description: Film-coated tablet with 10 mg macitentan, to be administered orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tadalafil 40 mg
Description: Film-coated tablet with 40 mg tadalafil (2 x 20 mg tablets), to be administered orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo FDC
Description: Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo FDC
Description: Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo macitentan
Description: Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo macitentan
Description: Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tadalafil
Description: Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tadalafil
Description: Matching placebo not containing any active substance but otherwise identical in appearance to the respective active drug tablet, to be administered orally once daily.
Study: NCT04088305

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Individualized therapy
Description: Dosage of Vancomycin decided by a serum trough concentration model, instead of decided by attending physician
Study: NCT01587703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762
Description: Begin at Dose Level 1 and increase up to 2 fold

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762
Description: Begin at Dose Level 1 and increase up to 2 fold

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK525762
Description: Begin at Dose Level 1 and increase up to 2 fold
Study: NCT03595306

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic A - inulin
Description: Pre-weighed packages will be given twice daily for 5 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic A - inulin
Description: Pre-weighed packages will be given twice daily for 5 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic A - inulin
Description: Pre-weighed packages will be given twice daily for 5 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic B - galactooligosaccharides(GOS)
Description: Pre-weighed packages will be given twice daily for 5 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic B - galactooligosaccharides(GOS)
Description: Pre-weighed packages will be given twice daily for 5 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic B - galactooligosaccharides(GOS)
Description: Pre-weighed packages will be given twice daily for 5 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic C - wheat dextrin
Description: Pre-weighed packages will be given twice daily for 5 days.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic C - wheat dextrin
Description: Pre-weighed packages will be given twice daily for 5 days.
Study: NCT03586999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab injection is to be administered as an IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisolone
Description: Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oncovin
Description: Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxydaunorubicin
Description: Dosage calculations will be based on the patient's body surface area (BSA) at baseline, recommend using the Mosteller formula and administered through IV. Dose adjustments at the beginning of each cycle do not need to be made unless there has been a \>10% weight gain or loss. Patients receive six 21-day cycles of the medications.
Study: NCT03204942

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PRF on DRG
Description: RF will be performed with the patient in a prone position with mild flexion of the spine. Fluoroscopy beam positioned in an antero-posterior direction. A 10 cm RF needle 20 G with a 10 mm active tip.The needle is inserted in a slightly medial-cephalad direction under the transverse processes, and using lateral fluoroscopic imaging, incrementally walking into the thoracic intervertebral foramen. So the location of the needle tip confirmed by sensory stimulation at 50 Hz. The point of maximum stimulation is at 0.5 V intensity and this is designated to be the location of the DRG. Slight redirection can be done to optimize the stimulation; injection of contrast reveals epidural uptake. After establishing the site for the RF, 1 ml 2% lidocaine should be injected through the needle.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: TRF on DRG
Description: Similar to the group of  PRF on DRG, but the types of the waves will be different as previously described

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroid injection
Description: Similar to the previous groups, but without applying any type of Radio-frequency but just injecting steroids and local anesthetics as previously described
Study: NCT03595306

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Prebiotic C - wheat dextrin
Description: Pre-weighed packages will be given twice daily for 5 days.
Study: NCT01817088

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: New targeting procedure without electrophysiology
Description: It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under general anaesthesia using a new targeting procedure without electrophysiology.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Classical neurosurgical procedure
Description: It is a neurosurgical procedure of electrodes implantation in the sub thalamic nuclei under awake surgery with electrophysiological control. A second surgical step is performed to implant the subcutaneous stimulation device, under general anesthesia.
Study: NCT03060356

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: T cells modified with RNA anti -cMET CAR
Description: Intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: T cells modified with RNA anti -cMET CAR
Description: Intravenously administered, RNA electroporated autologous T cells expressing MET chimeric antigen receptors with tandem TCRζ and 4-1BB (TCRζ /4-1BB) co-stimulatory domains
Study: NCT03150004

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine, Cytarabine, Mitoxantrone, G-CSF (CLAG-M) regimen
Description: Subjects will be started on CLAG-M regimen, which consists of the following:~* Cladribine 5 mg/m\^2 IV over two hours on days 1-5;~* Cytarabine 2 gm/m\^2 IV over four hours on days 1-5~* Mitoxantrone 10 mg/m\^2 IV on days 1-3;~* G-CSF at a dose of 300 μg on days 0-5.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cladribine and Cytarabine (CLLDAC) Regimen
Description: * Cladribine 5 mg/m\^2 IV over two hours on days 1-5;~* Cytarabine 20 mg/m\^2 subcutaneous injection on days 1-10;
Study: NCT01176747

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BDP/formoterol NEXT DPI
Description: Single inhalation of radiolabelled BDP/formoterol 100/6 µg NEXT DPI (4 puffs giving a total dose of 400 µg BDP + 24 µg formoterol)
Study: NCT02648737

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioural Therapy (CBT)
Description: Cognitive Behavioural Therapy (CBT) is considered the gold standard in psychotherapeutic treatments of anxiety. CBT is defined as: 'An amalgam of behavioural and cognitive problem-based interventions guided by principles of applied science. The behavioural interventions aim to decrease maladaptive behaviours and increase adaptive ones by modifying their antecedents and consequences and by behavioural practices that result in new learning. The cognitive interventions aim to modify maladaptive cognitions, self-statements, or beliefs.' (Arch \& Craske, 2009; Craske, 2010).

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical monitoring
Description: Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Clinical monitoring
Description: Patients assigned to clinical monitoring only will receive general education material on coping with PD symptoms and behavioural symptoms such as anxiety. In addition, they will be followed-up 1 month after baseline assessment via telephone calls to inquire about current anxiety symptoms. Patients will remain under the care of their personal physicians, who will also monitor their medical and psychiatric status.
Study: NCT02068079

Intervention type: DRUG
Group type: OTHER
Intervention: Vemurafenib and Trientine
Study: NCT02122354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hide and Seek videogame
Study: NCT03658018

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracept System Ablation
Description: Radiofrequency ablation using Intracept System
Study: NCT01810640

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Liver Biopsy
Description: Using a 16 gauge Jamshidi biopsy needle, without image guidance, 3 passes will be completed to obtain core liver biopsies. Biopsies will be placed on wet saline and processed via frozen sample in OCT compound in 5 micron slices and stained with hematoxylin and eosin for microscopic evaluation. Slides will then be digitalized and shared on Donor.net.
Study: NCT04594512

Intervention type: OTHER
Group type: OTHER
Intervention: Fresh corneal lenticule and autologous serum in advanced keratoconus using ReLex Smile surgery
Description: A 19-year-old female patient with keratoconus and chronic hydrops cornea referred to the cornea department of our clinic with thin cornea and hydrops in chronic stage and minimal dry eye symptoms. Minimum corneal pachymetry in the right eye was 378 µm as measured by optical coherence tomography(AS-OCT-Zeiss). Atlas corneal topography showed steep K-values 82.60 ax.37 and flat K 75.15 D ax 127 with -7.45 corneal astigmatism. Her best corrected visual acuity was 0.0.5 in right eye and 1.0 in the left eye. Slit lamp examination showed intense punctate epitheliopathy (Figure 1), tear film break-up time (TBUT) was measured as 7-8 sec and Schirmer test was 10 mm in right eye, and the other eye examinations were determined normally
Study: NCT02063165

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: High Linoleic Safflower Oil
Description: 2 tsp per day (\~10g of oil)
Study: NCT03698955

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Plant-based diet
Description: Weekly instructions will be given to the participants in the intervention group about following the vegan diet.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Mediterranean Diet
Description: Weekly instructions will be given to the participants in the intervention group about following the Mediterranean diet.
Study: NCT02829099

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64457107
Description: JNJ-64457107 administered by IV infusion on Day 1 and 14 of a 28-day cycle.
Study: NCT01986829

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Microwave ablation
Description: * Microwave ablation will be predominantly used on metastatic soft tissue lesions and will include use of Covidien's Evident™ MWA System. Microwave ablation is performed under ultrasound, CT, and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in probe placement and CT monitoring of ablation.~* Microwave antennae from Covidien (Mansfield, MA) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cryoablation
Description: * Cryoablation is performed under ultrasound, CT and occasional fluoroscopic guidance with CT fluoroscopy available for intermittent use in cyroprobe placement and CT monitoring of ablation.~* Cryoprobes from Endocare Inc. (Irvine CA) or Galil Medical (Arden Hills MN) are either introduced into the lesion co-axially through a bone biopsy needle or directly into the lesions that are amenable to such, i.e., soft tissue, lung, liver, and large lytic lesions with extensive bone destruction.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Radiofrequency ablation
Description: -Radiofrequency ablation will be predominantly used on metastatic spine lesions and will include use of the Dfine STAR ablation probe. This probe will be placed coaxially through an introducer needle into the spinal metastatic lesion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BPI-Short form
Description: -Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACT-G7
Description: -Prior to ablation, 1 day post-ablation, 1 month post-ablation (from first procedure if more than 1 is done), and time of disease progression
Study: NCT01377974

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Miltefosine
Description: 1 Capsule of 50mg, taken orally 2 times a day for 28 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment Meglumine antimoniate
Description: 20mgKg daily intravenous Meglumine antimoniate as oriented by the Brazilian Ministry of Health
Study: NCT02233231

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varenicline
Description: Varenicline 2 mg x 1 day 7 to week 12

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: similar tabl
Study: NCT00061490

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral weight control and lifestyle exercise
Description: 16 weekly educational meetings vs. waitlist control
Study: NCT01260922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Donepezil Hydrochloride
Description: 10 mg Orally Disintegrating Tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aricept®
Description: 10 mg Orally Disintegrating Tablet
Study: NCT03140891

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NHFOV
Description: NHFOV is used as the noninvasive mode after extubation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NCPAP
Description: NCPAP is used as the noninvasive mode after extubation
Study: NCT04068675

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group pre-operative counseling
Description: Enrolled patients will participate in a group pre-operative counseling session on the online conferencing platform BlueJeans® prior to their surgery. The sessions will not replace any portion of the pre-operative standard counseling and is designed to review and re-enforce the counseling already provided. The sessions will not review or discuss the specifics of any one individual's cancer or surgery. Rather the counseling session will focus on the universal instructions provided to all patients undergoing major surgery for a known or suspected gynecologic malignancy. The sessions will be led by a physician on a weekly basis with a minimal of three (3) enrolled patients per session and last approximately one (1) hour.
Study: NCT02248922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TIS or TIP
Description: 300mg nebulized Tobramycin (Tobramycin inhalation solution(TIS)) or TOBI Podhaler (Tobramycin inhalation powder(TIP), equivalent dry powder)
Study: NCT01229436

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Xiapex
Description: Xiapex 0.58 mg in diluent, 0.25 ml for MP joints and 0.20 ml for PIP joints, injection to cord over joint using either 26 or 27 gauge needle, maximum 3 injections with 30 days interval between injections to any single site, maximum 5 injections in this protocol